ADVANCES IN HEART FAILURE MANAGEMENT: SGLT2 INHIBITORS BEYOND DIABETES

Main Article Content

Dr. Abutalha Chauhan(Teacher) Dr PATEL SUFIYAN ABDULSAEED (Teacher) Dr. Ilma mansuri (Teacher)

Abstract

This article reviews the emerging role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of heart failure (HF), extending beyond their original use in managing type 2 diabetes mellitus. Recent landmark clinical trials have demonstrated that SGLT2 inhibitors such as dapagliflozin and empagliflozin significantly reduce cardiovascular mortality and hospitalization for heart failure in both diabetic and non-diabetic patients.


 

Article Details

Section
Articles

References

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., ... & DAPA-HF Trial Committees and Investigators. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/NEJMoa1911303

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & EMPEROR-Reduced Trial Investigators. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383(15), 1413–1424. https://doi.org/10.1056/NEJMoa2022190

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., ... & EMPEROR-Preserved Trial Investigators. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/NEJMoa2107038

Solomon, S. D., McMurray, J. J., Claggett, B., DeMets, D., Hernandez, A. F., Inzucchi, S. E., ... & DELIVER Trial Investigators. (2022). Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine, 387(12), 1089–1098. https://doi.org/10.1056/NEJMoa2206286

Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., ... & SOLOIST-WHF Trial Investigators. (2021). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 384(2), 117–128. https://doi.org/10.1056/NEJMoa2030183

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., ... & Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 79(17), 1757–1780. https://doi.org/10.1016/j.jacc.2022.01.031